Literature DB >> 28062019

Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database.

Saad Shakeel1, Laurie Elit2, Noori Akhtar-Danesh3, Laura Schneider1, Christian Finley1.   

Abstract

OBJECTIVES: In this pan-Canadian study, we sought to elucidate the current state of surgical care for primary ovarian cancers and factors influencing selected short-term outcomes; these were in-hospital mortality (IHM), major complications (MCs), failure-to-rescue (FTR), and hospital length of stay (LOS).
METHODS: We created a population cohort using inpatient admission records from the Canadian Institute of Health Information data set (2004-2012). Multilevel logistic regression and flexible parametric survival analyses, adjusted for hospital clustering effect, were conducted to determine the effect of patient-specific factors (i.e., age, comorbidities, and admission category); procedural complexity; and the surgical volume and specialty of each care provider on the outcomes of interest.
RESULTS: A total of 16 089 women underwent surgeries for primary ovarian cancer across Canada. The crude rates of IHM, MC, and FTR were 0.89%, 5.7%, and 9.09%, respectively, with a median LOS of four days (interquartile range 3 to 6). The majority of surgical procedures were performed by surgeons and hospitals with annual surgical volumes of less than five such procedures. Hospitals with higher surgical volumes were associated with lower risk of IHM (OR 0.95, 95% CI 0.91 to 0.99) and FTR (OR 0.95, 95% CI 0.91 to 0.99) and a higher chance of earlier discharge (hazard ratio [HR] 1.03, 95% CI 1.00 to 1.06). Surgeons with higher surgical volumes were associated with lower odds of early discharge (HR 0.90, 95% CI 0.87 to 0.94) and a higher risk of MC (OR 1.12, 95% CI 1.02 to 1.23). Compared with gynaecologic oncologists, general surgeons had a significantly higher risk of IHM (OR 3.50, 95% CI 1.82 to 6.74) and MC (OR 2.13, 95% CI 1.36 to 3.33) and lower odds of early discharge (HR 0.43, 95% CI 0.40 to 0.47).
CONCLUSION: Despite limitations in the administrative data set, valuable information was available for this pan-Canadian analysis. Our findings support centralization of surgical procedures for women with ovarian cancer in tertiary care centres with higher surgical volumes that are staffed by in-house multidisciplinary care teams and specialist surgeons.
Copyright © 2017 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ovarian cancer; centralization; quality of care; surgeon specialty; surgery; volume

Mesh:

Year:  2016        PMID: 28062019     DOI: 10.1016/j.jogc.2016.09.075

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  5 in total

1.  Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.

Authors:  Sarah P Huepenbecker; Hui Zhao; Charlotte C Sun; Shuangshuang Fu; Weiguo He; Sharon H Giordano; Larissa A Meyer
Journal:  JCO Clin Cancer Inform       Date:  2022-03

2.  Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway.

Authors:  Zhiying Qi; Lirong Yin; Yanying Xu; Fang Wang
Journal:  Mol Med Rep       Date:  2018-03-28       Impact factor: 2.952

3.  Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation.

Authors:  Kahren M White; Holly Seale; Reema Harrison
Journal:  BMC Public Health       Date:  2019-03-12       Impact factor: 3.295

4.  Patient and Provider Perspectives on Barriers to Accessing Gynecologic Oncologists for Ovarian Cancer Surgical Care.

Authors:  Kristin Weeks; Michele West; Charles Lynch; Lisa Hunter; Chelsea Keenan; Savannah Borman; Megan McDonald; Mary Charlton
Journal:  Womens Health Rep (New Rochelle)       Date:  2020-12-28

5.  Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.

Authors:  Kristin Weeks; Charles F Lynch; Michele West; Ryan Carnahan; Michael O'Rorke; Jacob Oleson; Megan McDonald; Sherri L Stewart; Mary Charlton
Journal:  Gynecol Oncol       Date:  2020-11-18       Impact factor: 5.482

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.